Optimizing prognosis in atrial fibrillation: A call to action in Portugal

Kirchhof, 2016, 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, 37, 2893, 10.1093/eurheartj/ehw210 Chugh, 2014, Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study, Circulation, 129, 837, 10.1161/CIRCULATIONAHA.113.005119 Naghavi, 2017, Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 390, 1151, 10.1016/S0140-6736(17)32152-9 Ferreira, 2017 Instituto Nacional de Estatística, 2017 Kamel, 2017, Cardioembolic stroke, Circ Res, 120, 514, 10.1161/CIRCRESAHA.116.308407 Sargento-Freitas, 2013, Atrial fibrillation in cerebrovascular disease: national neurological perspective, Acta Med Port, 26, 86, 10.20344/amp.85 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Lloyd-Jones, 2004, Lifetime risk for development of atrial fibrillation: the framingham heart study, Circulation, 110, 1042, 10.1161/01.CIR.0000140263.20897.42 Krijthe, 2013, Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060, Eur Heart J, 34, 2746, 10.1093/eurheartj/eht280 Bonhorst, 2010, Prevalência de fibrilhação auricular na população portuguesa com 40 ou mais anos. Estudo FAMA, Rev Port Cardiol, 29, 331 Primo, 2017, Prevalence of paroxysmal atrial fibrillation in a population assessed by continuous 24-hour monitoring, Rev Port Cardiol, 36, 535, 10.1016/j.repc.2016.11.005 Monteiro, 2018, study: A reflection on the prevalence and treatment patterns of atrial fibrillation and cardiovascular risk factors in 7500 elderly subjects, Rev Port Cardiol, 37, 307, 10.1016/j.repc.2017.08.006 Wolf, 1991, Atrial fibrillation as an independent risk factor for stroke: the Framingham study, Stroke, 983, 10.1161/01.STR.22.8.983 Peters, 2002, Atrial fibrillation: strategies to control, combat, and cure, Lancet, 359, 593, 10.1016/S0140-6736(02)07748-6 Kimura, 2005, Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke, J Neurol Neurosurg Psychiatry, 76, 679, 10.1136/jnnp.2004.048827 Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Huisman, 2018, Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry, Am Heart J, 198, 55, 10.1016/j.ahj.2017.08.018 Chao, 2018, Evolving changes of the use of oral anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation in Taiwan, Circulation, 138, 1485, 10.1161/CIRCULATIONAHA.118.036046 Ziegler, 2012, Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention, Am J Cardiol, 110, 1309, 10.1016/j.amjcard.2012.06.034 Sposato, 2015, Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis, Lancet Neurol, 14, 377, 10.1016/S1474-4422(15)70027-X Elijovich, 2009, Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors, J Stroke Cerebrovasc Dis, 18, 185, 10.1016/j.jstrokecerebrovasdis.2008.09.005 Kamel, 2014, Heart-rhythm monitoring for evaluation of cryptogenic stroke, N Engl J Med, 370, 2532, 10.1056/NEJMe1405046 Gladstone, 2014, Atrial fibrillation in patients with cryptogenic stroke, N Engl J Med, 370, 2467, 10.1056/NEJMoa1311376 Sanna, 2014, Cryptogenic stroke and underlying atrial fibrillation, N Engl J Med, 370, 2478, 10.1056/NEJMoa1313600 Freedman, 2017, Screening for atrial fibrillation, Circulation, 135, 1851, 10.1161/CIRCULATIONAHA.116.026693 Jones, 2020, Screening for atrial fibrillation: a call for evidence, Eur Heart J, 41, 1075, 10.1093/eurheartj/ehz834 Desteghe, 2017, Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting, Europace, 19, 29 Marazzi, 2012, Comparison of Microlife BP A200 Plus and Omron M6 blood pressure monitors to detect atrial fibrillation in hypertensive patients, Adv Ther, 29, 64, 10.1007/s12325-011-0087-0 Barrett, 2014, Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring, Am J Med, 127, 10.1016/j.amjmed.2013.10.003 Perez, 2019, Large-scale assessment of a smartwatch to identify atrial fibrillation, N Engl J Med, 381, 1909, 10.1056/NEJMoa1901183 Guo, 2019, Mobile photoplethysmographic technology to detect atrial fibrillation, J Am Coll Cardiol, 74, 2365, 10.1016/j.jacc.2019.08.019 Šimundić, 2009, Measures of diagnostic accuracy: basic definitions, EJIFCC, 19, 203 Calkins, 2009, Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses, Circ Arrhythmia Electrophysiol, 2, 349, 10.1161/CIRCEP.108.824789 Al-Khatib, 2014, Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review, Ann Intern Med, 160, 760, 10.7326/M13-1467 Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA Randomized Clinical Trial, JAMA, 321, 1261, 10.1001/jama.2019.0693 Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855 Kirchhof, 2013, Improving outcomes in patients with atrial fibrillation: rationale and design of the early treatment of atrial fibrillation for stroke prevention trial, Am Heart J, 166, 442, 10.1016/j.ahj.2013.05.015 Guo, 2017, Atrial fibrillation ablation: Indications, outcomes, complications, and future directions, Chin Med J (Engl), 130, 1891, 10.4103/0366-6999.211900 Di Biase, 2014, Circulation, 129, 2638, 10.1161/CIRCULATIONAHA.113.006426 Cappato, 2015, Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation, Eur Heart J, 36, 1805, 10.1093/eurheartj/ehv177 Calkins, 2017, Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation, N Engl J Med, 376, 1627, 10.1056/NEJMoa1701005 Kirchhof, 2018, Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation, Eur Heart J, 39, 2942, 10.1093/eurheartj/ehy176 Hohnloser, 2019, Uninterrupted edoxaban vs. Vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial, Eur Heart J, 40, 3013, 10.1093/eurheartj/ehz190 Calkins, 2019, Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study, EP Eur, 1 Di Biase, 2018, Safety and efficacy of uninterrupted direct oral anticoagulant administration in elderly patients undergoing catheter ablation of atrial fibrillation, JACC Clin Electrophysiol, 4, 601, 10.1016/j.jacep.2018.04.004 Yanagisawa, 2018, Uninterrupted direct oral anticoagulant and warfarin administration in elderly patients undergoing catheter ablation for atrial fibrillation: a comparison with younger patients, JACC Clin Electrophysiol, 4, 592, 10.1016/j.jacep.2018.02.013 Calkins, 2017, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Hear Rhythm, 14, e275, 10.1016/j.hrthm.2017.05.012 Freedman, 2016, Stroke prevention in atrial fibrillation, Lancet, 388, 806, 10.1016/S0140-6736(16)31257-0 Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, J Am Med Assoc, 285, 2864, 10.1001/jama.285.22.2864 Lip, 2010, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach, Chest, 137, 263, 10.1378/chest.09-1584 Lip, 2017, Stroke prevention in atrial fibrillation: past, present and future comparing the guidelines and practical decision-making, Thromb Haemost, 117, 1230, 10.1160/TH16-11-0876 Singer, 2013, A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score, J Am Heart Assoc, 2, e000250, 10.1161/JAHA.113.000250 Hijazi, 2016, The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation, Eur Heart J, 37, 1582, 10.1093/eurheartj/ehw054 Hamatani, 2016, Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation, Sci Rep, 6, 31042, 10.1038/srep31042 Lim, 2015, Management of atrial fibrillation: recommendations from NICE, Br J Hosp Med, 76, C108, 10.12968/hmed.2015.76.7.C108 Sulzgruber, 2019, Eur Heart J Cardiovasc Pharmacother, 5, 171, 10.1093/ehjcvp/pvz016 Lip, 2015, Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score, Thromb Haemost, 114, 826, 10.1160/TH15-07-0565 Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation, Chest, 138, 1093, 10.1378/chest.10-0134 Steffel, 2018, The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, 39, 1330, 10.1093/eurheartj/ehy136 Martinez, 2016, Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study, Thromb Haemost, 115, 31, 10.1160/TH15-04-0350 Gorst-Rasmussen, 2015, Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study, J Thromb Haemost, 13, 495, 10.1111/jth.12845 Shore, 2014, Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans Health Administration, Am Heart J, 167, 810, 10.1016/j.ahj.2014.03.023 Diener, 2017, Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1, Eur Heart J, 38, 852 Diener, 2017, Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: Part 2, Eur Heart J, 38, 860 Lauw, 2017, Effects of dabigatran according to age in atrial fibrillation, Heart, 103, 1015, 10.1136/heartjnl-2016-310358 Bohula, 2016, Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial, Circulation, 134, 24, 10.1161/CIRCULATIONAHA.116.022361 Bassand, 2018, Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation, PLOS ONE, 13, 1, 10.1371/journal.pone.0191592 Gómez-Outes, 2016, Causes of death in anticoagulated patients with atrial fibrillation, J Am Coll Cardiol, 68, 2508, 10.1016/j.jacc.2016.09.944 Chang, 2017, Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation, JAMA, 318, 1250, 10.1001/jama.2017.13883 Eikelboom, 2012, Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation, J Thromb Haemost, 10, 966, 10.1111/j.1538-7836.2012.04668.x Caldeira, 2015, antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis, Heart, 101, 1204, 10.1136/heartjnl-2015-307489 Majeed, 2013, Management and outcomes of major bleeding during treatment with dabigatran or warfarin, Circulation, 128, 2325, 10.1161/CIRCULATIONAHA.113.002332 Held, 2015, Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: Insights from the ARISTOTLE trial, Eur Heart J, 36, 1264, 10.1093/eurheartj/ehu463 Piccini, 2014, Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial, Eur Heart J, 35, 1873, 10.1093/eurheartj/ehu083 Tomaselli, 2017, 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways, J Am Coll Cardiol, 70, 3042, 10.1016/j.jacc.2017.09.1085 Pollack, 2017, Idarucizumab for dabigatran reversal – full cohort analysis, N Engl J Med, 377, 431, 10.1056/NEJMoa1707278 Connolly, 2019, Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors, N Engl J Med, 380, 1326, 10.1056/NEJMoa1814051 Hart, 2012, Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial, Stroke, 43, 1511, 10.1161/STROKEAHA.112.650614 Desai, 2013, Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies, Thromb Haemost, 110, 205, 10.1160/TH13-02-0150 Satasivam, 2012, The effect of oral anticoagulation on the prevalence and management of haematuria in a contemporary Australian patient cohort, BJU Int, 110, 80, 10.1111/j.1464-410X.2012.11622.x Zweiker, 2017, Association between subjective risk perception and objective risk estimation in patients with atrial fibrillation: a cross-sectional study, BMJ Open, 7 Reddy, 2013, Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial, Circulation, 127, 720, 10.1161/CIRCULATIONAHA.112.114389 Holmes, 2014, Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial, J Am Coll Cardiol, 64, 1, 10.1016/j.jacc.2014.04.029 Marijon, 2013, Causes of death and influencing factors in patients with Atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study, Circulation, 128, 2192, 10.1161/CIRCULATIONAHA.112.000491 Cleland, 2001, The heart failure epidemic: exactly how big is it?, Eur Heart J, 22, 623, 10.1053/euhj.2000.2493 Nieuwlaat, 2009, Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation results of the Euro Heart Survey on Atrial Fibrillation, J Am Coll Cardiol, 53, 1690, 10.1016/j.jacc.2009.01.055 Maisel, 2003, Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy, Am J Cardiol, 91, 2D, 10.1016/S0002-9149(02)03373-8 Dries, 1998, Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials, J Am Coll Cardiol, 32, 695, 10.1016/S0735-1097(98)00297-6 Hart, 2007, Independent predictors of stroke in patients with atrial fibrillation: a systematic review, Neurology, 69, 546, 10.1212/01.wnl.0000267275.68538.8d Friberg, 2016, Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries, Eur Heart J, 37, 2478, 10.1093/eurheartj/ehw087 Lau, 2017, Modifiable risk factors and atrial fibrillation, Circulation, 136, 583, 10.1161/CIRCULATIONAHA.116.023163 Voskoboinik, 2020, Alcohol abstinence in drinkers with atrial fibrillation, N Engl J Med, 382, 20, 10.1056/NEJMoa1817591 Zelniker, 2020, Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 Trial, Circulation, 141, 1227, 10.1161/CIRCULATIONAHA.119.044183 Böhm, 2019, Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial, Eur J Heart Fail, 22, 126, 10.1002/ejhf.1663